Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
November 12, 2019 AUROBINDO To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Sandra Kurla Complex, Sandra (E), Phiroz Jeejeebhoy Towers, MUMBAI ·400 051 25 th floor, Dalal Street, MUMBAI ·400 001 Company Code No. AUROPH
Slide 2: Aurobindo Pharma Q2 FY20 Earnings Presentation
Aurobindo Pharma Q2 FY20 Earnings Presentation 12th November 2019
Slide 3: Safe Harbor Statement
Aurobindo Pharma Limited – Earnings Presentation 2 Safe Harbor Statement This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or se
Slide 4: Index
Aurobindo Pharma Limited – Earnings Presentation 3 Index 1 Q2FY20 Financial & Business Highlights 2 Financial Performance 3 Filings Snapshot
Slide 5: Q2 FY20 Financial & Business Highlights
1 Q2 FY20 Financial & Business Highlights 4
Slide 6: Consolidated Financial Highlights – Q2FY20
Aurobindo Pharma Limited – Earnings Presentation 5 Consolidated Financial Highlights – Q2FY20 Key Financial Highlights • Revenue from operations grew by 17.9% to Rs 5,600.5 crore • EBIDTA before forex and other income at Rs 1,167.5 crore, an increase of 13.8% over Q2FY19; EBITDA margin for the quart
Slide 7: Q2 FY20 Financial Highlights
Aurobindo Pharma Limited – Earnings Presentation 6 Q2 FY20 Financial Highlights Revenue (Rs Crore) EBITDA (Rs Crore) Net Profit (Rs Crore) 5,600 1,167 640 4,751 611 1,026 Q2FY19 Q2FY20 Q2FY19 Q2FY20 Q2FY19 Q2FY20 Revenue Mix Business Revenue Mix ANDAs Status Growth API Filings Approvals Markets 14.4
Slide 8: Consistent Quarterly Performance
Aurobindo Pharma Limited – Earnings Presentation 7 Consistent Quarterly Performance Revenue (Rs Crore) US Revenue (US$ mn) 5,445 5,600 404 5,270 5,292 387 339 353 4,751 318 4,250 271 282 4,049 Q4FY18 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 Q2FY20 Q4FY18 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 Q2FY20 EBITDA (R
Slide 9: US Business Performance Highlights
Aurobindo Pharma Limited – Earnings Presentation 8 US Business Performance Highlights Revenue (Rs. Crore) Revenue Mix Q2FY20 2,835 Orals 2,227 63% Branded Oncology 6% Dietary Supplements 10% OTC 3% Injectables* 19% Q2FY19 Q2FY20 US Formulations • US revenue for Q2FY20 witnessed a growth of 27% YoY t
Slide 10: Europe, ARV, Growth Markets, API Business Performance Highlights
Aurobindo Pharma Limited – Earnings Presentation 9 Europe, ARV, Growth Markets, API Business Performance Highlights Rs. Crore Europe Growth Markets ARV API 1,401 319 817 806 307 238 244 1,157 Q2FY19 Q2FY20 Q2FY19 Q2FY20 Q2FY19 Q2FY20 Q2FY19 Q2FY20 • Europe formulations revenue • Growth Markets reven
Slide 11: Financial Performance
2 Financial Performance 10
Slide 12: Consolidated Financial Performance
Aurobindo Pharma Limited – Earnings Presentation 11 Consolidated Financial Performance Value Rs Crore Q2FY20 Q2FY19 YoY growth(%) Q1FY20 QoQ growth(%) Formulations 4,793.8 3,934.8 21.8 4,712.0 1.7 API 805.8 816.6 -1.3 732.2 10.1 Formulations % of sales 85.6% 82.8% 86.6% Revenue from Operations 5,600
Slide 13: Debt Profile
Aurobindo Pharma Limited – Earnings Presentation 12 Debt Profile Fx Loan US$ Mn Debt as on (Rs Crore) Mar-17 Mar-18 Mar-19 Jun-19 Sep-19 Closing Rate1 US$ = INR 64.85 65.17 69.155 69.020 70.875 481 731 1,006 850 828 Fx Loan restated in INR 3,121.5 4,766.9 6,959.0 5,865.4 5,866.8 Rupee Loan 244.8 4.1
Slide 14: Filings Snapshot
3 Filings Snapshot 13
Slide 15: US Filings Snapshot
Aurobindo Pharma Limited – Earnings Presentation 14 US Filings Snapshot 318 Dermatology, Nasals and Opthalmic 569 541 71 Includes ANDAs of Orals, OTC, 478 429 138 153 398 117 Non - Injectables 26 27 115 Injectables 147 34 38 133 47 36 377 389 327 276 215 31-Mar-16 31-Mar-17 31-Mar-18 31-Mar-19 30-Se
Slide 16: Global Filing details
Aurobindo Pharma Limited – Internal Presentation 15 Global Filing details As at As at As at As at As at As at As at As at Category Approvals Mar 14 Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 June 19 Sep 19 Formulations US* 336 376 398 429 478 541 551 569 416 (FA: 389, TA:27) 2,506 Dossiers (273 Europe** 1,5
Slide 17: Thank You
Thank You Investors Contact: Investor Relations team ir@aurobindo.com 040-66725401, +91 98486 67906